{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:03:05Z","timestamp":1790114585433,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":292,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Academician Jie-shou Li Intestinal Barrier Special Research Fund","award":["LJS-201908C"],"award-info":[{"award-number":["LJS-201908C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Thalidomide is applied in therapy for refractory Crohn's disease (CD) in adults, but systematic and rigorous clinical evidence is scant. The aim was to provide theoretical references for the efficacy of thalidomide in the therapy for refractory CD in adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A double-center, double-blind, placebo-controlled, randomized clinical trial of refractory CD in adults in two inflammatory bowel disease centers in China. In the double-blind trial, patients were randomly assigned to 100\u2009mg of thalidomide or placebo daily for 8\u2009weeks. The primary outcome was considered as the clinical remission rate calculated based on the Crohn's disease activity index at the eighth week following thalidomide or placebo treatment. In open label, non-response to placebo was additionally treated with 8\u2009weeks of thalidomide; all responders were continuously treated with thalidomide until the 48th week.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-five patients were randomly assigned to each group. At the eighth week, the clinical remission rate in the thalidomide group was significantly higher than that in the placebo group (68.0% [17\/25] vs 16.0% [4\/25]; relative risk, 4.2; 95% confidence interval, 1.8\u201310.9, P\u2009&amp;lt;\u20090.001). After a 48-week follow-up, the continuous treatment rate of thalidomide was 46.3% (19\/41). Adverse events during the whole process were reported in 58.5% of patients, mainly involving drowsiness, rash, and peripheral neuropathy that were mild and tolerable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Thalidomide can be used in the induction and maintenance therapy of refractory CD in adults. And it could be one of the treatment options for refractory CD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/gastro\/goac052","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T18:18:22Z","timestamp":1666289902000},"source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and safety of thalidomide in the treatment of refractory Crohn's disease in adults: a double-center, double-blind, randomized\u2013controlled trial"],"prefix":"10.1093","volume":"10","author":[{"given":"Xiang","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University , Hangzhou, Zhejiang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Zhang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Jin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University , Hangzhou, Zhejiang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University , Guangzhou, Guangdong, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2022102014385076100_goac052-B1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000000525","article-title":"Inflammatory bowel disease in children of Manitoba: 30 years' experience of a tertiary center","volume":"59","author":"El-Matary","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022102014385076100_goac052-B2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102014385076100_goac052-B3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/gastro\/goaa069","article-title":"Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study","volume":"9","author":"Ye","year":"2021","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2022102014385076100_goac052-B4","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2022102014385076100_goac052-B5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2022102014385076100_goac052-B6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"2022102014385076100_goac052-B7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40272-014-0070-8","article-title":"Pediatric ulcerative colitis: a practical guide to management","volume":"16","author":"Regan","year":"2014","journal-title":"Paediatr Drugs"},{"key":"2022102014385076100_goac052-B8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/ajg.2011.211","article-title":"The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety","volume":"106","author":"Van Assche","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2022102014385076100_goac052-B9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"2022102014385076100_goac052-B10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"2022102014385076100_goac052-B11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.2006.03239.x","article-title":"Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies","volume":"25","author":"Plamondon","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2022102014385076100_goac052-B12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2022102014385076100_goac052-B13","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"2022102014385076100_goac052-B14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"2022102014385076100_goac052-B15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"2022102014385076100_goac052-B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.13057","article-title":"Long-term outcomes of thalidomide in refractory Crohn's disease","volume":"41","author":"Gerich","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2022102014385076100_goac052-B17","doi-asserted-by":"crossref","first-page":"goac032.","DOI":"10.1093\/gastro\/goac032","article-title":"Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults","volume":"10","author":"Chen","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2022102014385076100_goac052-B18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2036.2010.04541.x","article-title":"Review article: the role of non-biological drugs in refractory inflammatory bowel disease","volume":"33","author":"Ng","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2022102014385076100_goac052-B19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"2022102014385076100_goac052-B20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MPG.0b013e318228349e","article-title":"Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab","volume":"54","author":"Felipez","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022102014385076100_goac052-B21","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"2022102014385076100_goac052-B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/14740338.3.1.47","article-title":"Thalidomide: an old drug with new clinical applications","volume":"3","author":"Laffitte","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"2022102014385076100_goac052-B23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/07853890108995961","article-title":"Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature","volume":"33","author":"Ginsburg","year":"2001","journal-title":"Ann Med"},{"key":"2022102014385076100_goac052-B24","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"key":"2022102014385076100_goac052-B25","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ibd.22845","article-title":"Amenorrhea in women treated with thalidomide: report of two cases and literature review","volume":"19","author":"Lazzerini","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022102014385076100_goac052-B26","doi-asserted-by":"crossref","first-page":"e6540","DOI":"10.1097\/MD.0000000000006540","article-title":"Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients","volume":"96","author":"Peng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2022102014385076100_goac052-B27","first-page":"765","article-title":"Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature","volume":"8","author":"Fabi","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"2022102014385076100_goac052-B28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrgastro.2009.221","article-title":"Optimizing the safety of biologic therapy for IBD","volume":"7","author":"de Silva","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022102014385076100_goac052-B29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002018-200629040-00003","article-title":"Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programme","volume":"29","author":"Uhl","year":"2006","journal-title":"Drug Saf"},{"key":"2022102014385076100_goac052-B30","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.critrevonc.2013.05.012","article-title":"Role of thalidomide in the treatment of patients with multiple myeloma","volume":"88","author":"Morgan","year":"2013","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goac052\/46580550\/goac052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goac052\/46580550\/goac052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T18:19:00Z","timestamp":1666289940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goac052\/6764648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goac052","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"goac052"}}